National Animal Shelter & Rescue Appreciation Week Support A Shelter Today!
Updated Consensus Offers Holistic Roadmap for Type 2 Diabetes Management
Guest Contributor
The landscape of type 2 diabetes management continues to evolve, and a new joint consensus report on the management of type 2 diabetes signals another important step forward. The American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) have released an updated guidance document that broadens the focus from blood sugar alone to a truly comprehensive view of health. For anyone interested in type 2 diabetes care, from clinicians to people living with the condition, this new approach to type 2 diabetes management offers a more integrated and preventive roadmap.
This 2026 consensus report builds on a collaboration between the ADA and EASD that has been in place since 2006 and was last updated in 2022. The document, published in Diabetes Care and Diabetologia, is designed to guide care for non-pregnant adults with type 2 diabetes. Led by chairs John Buse, MD, PhD, and Melanie Davies, CBE, MBChB, MD, the panel revisited how best to manage a condition that affects millions worldwide and is linked with multiple organ systems and long-term complications.
Joshua J. Neumiller, PharmD, CDCES, the ADA’s senior vice president of medical affairs, highlighted a key shift in thinking. He noted that the consensus reflects a “significant evolution” toward a broader management approach that looks not only at glucose, but also at individualized weight management and protection of the heart, kidneys, and liver. The idea is not simply to control diabetes in isolation. Instead, the report encourages developing a care plan that helps people thrive while living with diabetes, with attention to the many areas of health the condition can touch.
One of the central themes is earlier, proactive intervention. The report emphasizes that starting appropriate glucose-lowering medications sooner in the course of type 2 diabetes may help prevent the long-term complications that can accumulate over time. This reflects growing recognition that waiting for problems to appear before treating aggressively can miss an opportunity to change the overall trajectory of the disease.
Another important recommendation is the earlier use of specific medication classes, particularly SGLT2 inhibitors and GLP-1 based therapies. These treatments are not presented solely as tools for lowering blood sugar. According to the consensus, they can modify the course of type 2 diabetes itself and reduce the risk of complications. The report underscores that therapy should be tailored to each individual, especially with regard to their cardiovascular and chronic kidney disease risk. That tailored strategy aligns with a more personalized model of care that has been gaining ground in many areas of medicine.
The authors also expand the lens on which health conditions deserve regular attention in people with type 2 diabetes. Traditional diabetes monitoring has focused heavily on eyes, feet, and kidneys, given the well-known complications of retinopathy, neuropathy, and nephropathy. While these remain crucial areas of care, the new consensus calls for more prominent focus on other conditions that commonly coexist with type 2 diabetes.
Among these are heart failure and metabolic dysfunction associated steatotic liver disease, which is increasingly recognized in people with metabolic risk factors. The report also draws attention to obstructive sleep apnea, a condition that can affect energy, concentration, and overall health, and that often goes underdiagnosed. Mental health conditions, including anxiety and depression, receive specific mention as well. Acknowledging these challenges within a diabetes care plan can help address the emotional and psychological dimensions of living with a chronic condition. Periodontal health is included too, reflecting evidence that gum disease and diabetes can influence each other in complex ways.
I found this wide-ranging list striking because it formalizes what many people living with type 2 diabetes already experience in their daily lives: the condition does not exist in isolation. By including these coexisting conditions directly in the consensus, the ADA and EASD are encouraging clinicians to build care plans that view the person as a whole, rather than focusing narrowly on one lab value or one organ system.
The report also includes an updated algorithm for choosing and sequencing glucose-lowering medications. While the technical details lie within the full document, the core purpose is to help clinicians make evidence-informed decisions that fit the individual’s health status, preferences, and risk profile. In practice, this can mean selecting therapies not simply on their ability to lower blood sugar, but also on their effects on weight, cardiovascular outcomes, kidney health, and other key endpoints.
Lifestyle remains a cornerstone of care, and the consensus reinforces the importance of nutrition and other behavioral strategies alongside medications. A notable addition is an updated 24-hour framework that organizes and supports healthy behaviors across the full day. This framework encourages thinking about daily life in an integrated way, from eating patterns and physical activity to sleep and other routines that influence metabolic health. The idea is to move beyond isolated advice into a structure that can help people align their habits with their health goals, hour by hour.
Rita Kalyani, MD, MHS, consensus co-author and the ADA’s chief scientific and medical officer, emphasized the potential impact of this broader approach. She noted that the expanded focus creates opportunities for “more clinically meaningful sustained improvements” in metabolic health, organ protection, weight and body composition management, functional health, and multiple long-term outcomes. That phrase “sustained improvements” is key. Type 2 diabetes is a chronic condition, and strategies that support durable benefits over years matter greatly for quality of life.
What emerges from this consensus is an integrated model of type 2 diabetes care. It invites health professionals to start effective therapies earlier, address multiple organs and systems simultaneously, and pay consistent attention to mental and oral health. It also underscores the importance of tailoring treatment to the individual’s unique profile, including cardiovascular and kidney risks, rather than applying a one-size-fits-all template.
For people living with type 2 diabetes and their support networks, this shift offers a hopeful message. Care is moving toward a model in which blood sugar, weight, heart, kidney, and liver health, as well as sleep and emotional wellbeing, are all part of the same conversation. As the ADA and EASD continue to collaborate on these consensus statements, they are helping to translate research into practical guidance that can improve everyday clinical practice and, ultimately, long-term outcomes.
